CAS NO. |
Products Name |
1323403-33-3 |
EED226 |
more... |
Iberdomide (CC-220) is a cereblon modulator in clinical development for systemic lupus erythematosis. Iberdomide exhibits an IC50 of 60 nM in TR-FRET cereblon binding assay |
|
1323403-33-3 |
CC220 |
more... |
Iberdomide (CC-220) is a cereblon modulator in clinical development for systemic lupus erythematosis. Iberdomide exhibits an IC50 of 60 nM in TR-FRET cereblon binding assay |
|
545395-94-6 |
AMG9810 |
more... |
AMG9810 is a selective and competitive vanilloid receptor 1 (TRPV1) antagonist with IC50 values of 24.5 and 85.6 nM for human and rat TRPV1, repectively |
|
|
1435467-37-0 |
PF-06282999 |
more... |
PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases. |
|
|
|
1337883-32-5 |
DiZPK |
more... |
DiZPK is a genetically encoded, highly efficient photocrosslinking amino acid valuable in unveiling the physiological interaction partners of given proteins and their functions |
|
|
1338540-63-8 |
OTS514 |
more... |
OTS514 is a highly potent TOPK inhibitor with an IC50 value of 2.6 nM. IC50 value: 2.6 nM Target: TOPK in vitro: OTS514 can inhibit TOPK kinase activity. OTS514 strongly inhibits the growth of the TOPK-positive cancer cell lines with low IC50 values ranging from 1.5 to 14 nM. OTS514 strongly suppresses the growth of TOPK-positive cancer cells. |
|
957485-64-2 |
FPH2(BRD-9424) |
more... |
FPH2 induces of functional proliferation of primary human hepatocytes and may lead to the development of new therapeutics for liver diseases. |
|
2012607-27-9 |
WNK463 |
more... |
WNK463 is an orally bioavailable pan-WNK-kinase inhibitor. In vivo: WNK463, that exploits unique structural features of the WNK kinases for both affinity and kinase selectivity. In rodent models of hypertension, WNK463 affects blood pressure and body fluid and electro-lyte homeostasis, consistent with WNK-kinase-associated physiology and pathophysiology |
|